Regeneron Pharmaceuticals has reported encouraging results from the Phase I/II LINKER-MM1 clinical trial of its investigational bispecific antibody, linvoseltamab, in patients with relapsed/refractory multiple myeloma (r/r MM).
LINKER-MM1 is an open-label, multicentre, ongoing dose-escalation and dose-expansion trial that has enrolled 282 patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The completed Phase I dose-escalation part of the trial evaluated the tolerability, safety and dose-limiting toxicities across nine linvoseltamab dose levels, apart from various administration regimens.
The Phase II dose expansion segment is underway to analyse the safety and anti-tumour activity of linvoseltamab, with the primary endpoint being the objective response rate (ORR).
Key secondary endpoints comprise duration of response (DOR), progression-free survival (PFS), the rate of minimum residual disease (MRD) negative status, and overall survival (OS).
Findings after an 11-month median follow-up showed that the treatment with linvoseltamab offered a 71% ORR, with 46% of patients achieving a complete response (CR) or better.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe median time to response was one month, with the median time to a very good partial response (VGPR) or better being three months, and to a CR or better being eight months.
The median DoR, PFS, and OS were not reached at the time of reporting.
After 12 months, the estimated probability of maintaining a response was 78%, being progression-free was 69%, and survival was 75%.
Among patients who achieved a CR or better and were MRD evaluable, 93% were MRD negative at 10⁻⁵.
The trial also included a response-adapted regimen allowing patients to shift to every four-week dosing upon achieving a VGPR or better after at least 24 weeks of therapy.
Of the patients eligible for this extended dosing regimen, 90% were able to transition, and 48% of those who transitioned before achieving a CR experienced a deepening of response to CR or better.
Cytokine release syndrome (CRS) was the most common treatment-emergent adverse event, occurring in 46% of patients.
The latest development comes after the US Food and Drug Administration issued complete response letters for the company’s biologics license application for odronextamab in r/r follicular lymphoma and r/r diffuse large B-cell lymphoma.
